Patents by Inventor Charles Phillip Morris
Charles Phillip Morris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090291432Abstract: The present invention relates to a method for profiling an individual or group of individuals with respect to a neurological, psychiatric or psychological condition, phenotype or state, including a sub-threshold neurological, psychiatric or psychological condition, phenotype or state. More particularly, the present invention identifies a genetic profile associated with the 957C>T polymorphysm within the dopamine receptor D2 (DRD2), indicating a predisposition to schizophrenia and other neurological diseases.Type: ApplicationFiled: June 1, 2005Publication date: November 26, 2009Applicants: Queensland University Of Technology, The State Of Queensland (Queensland Health)Inventors: Charles Phillip Morris, Angela Van Daal, Christopher Dean Swagell, Bruce Robert Lawford, Ross McDonald Young
-
Patent number: 6541254Abstract: The present invention provides a highly glycosylated iduronate-2-sulfatase enzyme comprising an iduronate-2-sulfatase polypeptide with at least 5 kilodalton (kDa) more sugar than iduronate-2-sulfatase purified from a natural source, e.g. human liver. The present invention also provides an enzymatically active polypeptide fragment or variant of such a highly glycosylated iduronate-2-sulfatase. The present invention further provides an isolated nucleic acid encoding iduronate-2-sulfatase, as well as an expression vector, a host cell and a method for producing the present highly glycosylated iduronate-2-sulfatase enzyme.Type: GrantFiled: October 10, 2000Date of Patent: April 1, 2003Assignee: Women's and Children's HospitalInventors: Peter J. Wilson, Charles Phillip Morris, Donald Stewart Anson, Teresa Occhiodoro, Julie Bielicki, Peter Roy Clements, John Joseph Hopwood
-
Patent number: 6524835Abstract: The present invention relates generally to &agr;-L-iduronidase and to genetic sequences encoding same. More particularly, the present invention provides an isolated nucleic acid molecule comprising a sequence of nucleotides which encodes or are complementary to a sequence which encodes a mammalian &agr;-L-iduronidase or fragment or derivative thereof and to the recombinant enzyme encoded thereby. These molecules are useful in the investigation, diagnosis and treatment of subjects suspected of or suffering from &agr;-L-iduronidase deficiency.Type: GrantFiled: August 16, 2000Date of Patent: February 25, 2003Assignee: Women's and Children's HospitalInventors: Hamish Steel Scott, Donald Stewart Anson, Annette Marie Orsborn, Paul Victor Nelson, Peter Roy Clements, Charles Phillip Morris, John Joseph Hopwood
-
Patent number: 6491913Abstract: The present invention relates generally to mammalian sulphamidase and to genetic sequences encoding same and to the use of these in the investigation, diagnosis and treatment of subjects suspected of or suffering from sulphamidase deficiency.Type: GrantFiled: December 4, 2000Date of Patent: December 10, 2002Assignee: Women's and Children's HospitalInventors: John Joseph Hopwood, Hamish Steele Scott, Craig Geoffrey Freeman, Charles Phillip Morris, Lianne Cheryl Blanch, Xiao Hui Guo
-
Patent number: 6458579Abstract: The present invention relates generally to mammalian sulphamidase and to genetic sequences encoding same and to the use of these in the investigation, diagnosis and treatment of subjects suspected of or suffering from sulphamidase deficiency.Type: GrantFiled: December 4, 2000Date of Patent: October 1, 2002Assignee: Women's and Children's HospitalInventors: John Joseph Hopwood, Hamish Steele Scott, Craig Geoffrey Freeman, Charles Phillip Morris, Lianne Cheryl Blanch, Xiao Hui Guo
-
Publication number: 20020106358Abstract: The present invention relates generally to mammalian sulphamidase and to genetic sequences encoding same and to the use of these in the investigation, diagnosis ad treatment of subjects suspected of or suffering from sulphamidase deficiency.Type: ApplicationFiled: December 4, 2000Publication date: August 8, 2002Inventors: John Joseph Hopwood, Hamish Steele Scott, Craig Geoffrey Freeman, Charles Phillip Morris, Lianne Cheryl Blanch, Xiao Hui Guo
-
Publication number: 20010014323Abstract: The present invention relates generally to mammalian sulphamidase and to genetic sequences encoding same and to the use of these in the investigation, diagnosis and treatment of subjects suspected of or suffering from sulphamidase deficiency.Type: ApplicationFiled: December 4, 2000Publication date: August 16, 2001Inventors: John Joseph Hopwood, Hamish Steele Scott, Craig Geoffrey Freeman, Charles Phillip Morris, Lianne Cheryl Blanch, Xiao Hui Guo
-
Patent number: 6238662Abstract: The present invention relates generally to &agr;-L-iduronidase and to genetic sequences encoding same. More particularly, the present invention provides an isolated nucleic acid molecule comprising a sequence of nucleotides which encodes or are complementary to a sequence which encodes a mammalian &agr;-L-iduronidase or fragment or derivative thereof and to the recombinant enzyme encoded thereby. These molecules are useful in the investigation, diagnosis and treatment of subjects suspected of or suffering from &agr;-L-iduronidase deficiency.Type: GrantFiled: August 30, 1999Date of Patent: May 29, 2001Assignee: Women's and Children's HospitalInventors: Hamish Steel Scott, Donald Stewart Anson, Annette Marie Orsborn, Paul Victor Nelson, Peter Roy Clements, Charles Phillip Morris, John Joseph Hopwood
-
Patent number: 6200563Abstract: The present invention relates generally to mammalian sulphamidase and to genetic sequences encoding same and to the use of these in the investigation, diagnosis and treatment of subjects suspected of or suffering from sulphamidase deficiency.Type: GrantFiled: August 9, 1999Date of Patent: March 13, 2001Assignee: Women's and Children's HospitalInventors: John Joseph Hopwood, Hamish Steele Scott, Craig Geoffrey Freeman, Charles Phillip Morris, Lianne Cheryl Blanch, Xiao Hui Guo
-
Patent number: 6153188Abstract: The present invention provides a highly glycosylated iduronate-2-sulfatase enzyme comprising an iduronate-2-sulfatase polypeptide with at least 5 kilodalton (kDa) more sugar than iduronate-2-sulfatase purified from a natural source, e.g. human liver. The present invention also provides an enzymatically active polypeptide fragment or variant of such a highly glycosylated iduronate-2-sulfatase. The present invention further provides an isolated nucleic acid encoding iduronate-2-sulfatase, as well as an expression vector, a host cell and a method for producing the present highly glycosylated iduronate-2-sulfatase enzyme.Type: GrantFiled: February 12, 1999Date of Patent: November 28, 2000Assignee: Women's and Children's HospitalInventors: Peter J. Wilson, Charles Phillip Morris, Donald Stewart Anson, Teresa Occhiodoro, Julie Bielicki, Peter Roy Clements, John Joseph Hopwood
-
Patent number: 6149909Abstract: The present invention relates generally to .alpha.-L-iduronidase and to genetic sequences encoding same. More particularly, the present invention provides an isolated nucleic acid molecule comprising a sequence of nucleotides which encodes or are complementary to a sequence which encodes a mammalian .alpha.-L-iduronidase or fragment or derivative thereof and to the recombinant enzyme encoded thereby. These molecules are useful in the investigation, diagnosis and treatment of subjects suspected of or suffering from .alpha.-L-iduronidase deficiency.Type: GrantFiled: November 13, 1998Date of Patent: November 21, 2000Assignee: Women's and Children's HospitalInventors: Hamish Steele Scott, Donald Stewart Anson, Annette Marie Orsborn, Paul Victor Nelson, Peter Roy Clements, Charles Phillip Morris, John Joseph Hopwood
-
Patent number: 6017738Abstract: A method for detecting a target nucleic acid sequence comprises: (a) providing a first primer hybridizing to the target nucleic acid sequence, wherein the primer is immobilized on an immobile solid phase support by a direct chemical linkage between the primer and the solid phase support, wherein the solid phase support forms a part of or is insertable into a container for a sample to be tested, (b) providing a second primer hybridizing to the target nucleic acid sequence in the opposite direction, wherein the second primer is labelled with a detectable label, (c) reacting the first and second primers with a sample containing nucleic acid sequences under conditions which allow amplification of the nucleic acid sequences that hybridize to the first and second primers in the container for the sample, and (d) detecting the presence of bound second primer. Alternatively, the label on the second primer can be attached or incorporated either during or after the amplification process.Type: GrantFiled: December 9, 1996Date of Patent: January 25, 2000Assignees: Adelaide Children's Hospital, University of South AustraliaInventors: Charles Phillip Morris, Raymond John Harris
-
Patent number: 5972333Abstract: The present invention relates generally to mammalian sulphamidase and to genetic sequences encoding same and to the use of these in the investigation, diagnosis and treatment of subjects suspected of or suffering from sulphamidase deficiency.Type: GrantFiled: June 13, 1997Date of Patent: October 26, 1999Assignee: Women's and Children HospitalInventors: John Joseph Hopwood, Hamish Steele Scott, Craig Geoffrey Freeman, Charles Phillip Morris, Lianne Cheryl Blanch, Xiao Hui Guo
-
Patent number: 5932211Abstract: The present invention provides a highly glycosylated iduronate-2-sulfatase enzyme comprising an iduronate-2-sulfatase polypeptide with at least 5 kilodalton (kDa) more sugar than iduronate-2-sulfatase purified from a natural source, e.g. human liver. The present invention also provides an enzymatically active polypeptide fragment or variant of such a highly glycosylated iduronate-2-sulfatase. The present intention further provides an isolated nucleic acid encoding iduronate-2-sulfatase, as well as an expression vector, a host cell and a method for producing the present highly glycosylated iduronate-2-sulfatase enzyme.Type: GrantFiled: November 28, 1994Date of Patent: August 3, 1999Assignee: Women's and Children's HospitalInventors: Peter J. Wilson, Charles Phillip Morris, Donald Stewart Anson, Teresa Occhiodoro, Julie Bielicki, Peter Roy Clements, John Joseph Hopwood
-
Patent number: 5863782Abstract: The present invention relates generally to mammalian sulphamidase and to genetic sequences encoding same and to the use of these in the investigation, diagnosis and treatment of subjects suspected of or suffering from sulphamidase deficiency.Type: GrantFiled: April 19, 1995Date of Patent: January 26, 1999Assignee: Women's and Children's HospitalInventors: John Joseph Hopwood, Hamish Steele Scott, Craig Geoffrey Freeman, Charles Phillip Morris, Liane Cheryl Blanch, Xiao-Nui Guo
-
Patent number: 5849544Abstract: This method for detecting a target nucleic acid sequence involves amplification and detection in the same vessel and comprises: (a) amplification of the target nucleic sequence in a vessel which is provided with a solid phase capture probe comprising a nucleic acid sequence capable of hybridizing to at least a portion of said amplified target nucleic acid sequence, said capture probe being incapable of participating or not participating in standard nucleic acid sequence amplification processes, (b) bringing a sample suspected of comprising said target nucleic acid sequence into contact with said capture probe under conditions which allow said amplified target nucleic acid sequence to be bound by said capture probe, and (c) detecting the presence of bound target nucleic acid sequence.Type: GrantFiled: January 24, 1995Date of Patent: December 15, 1998Assignees: University of Australia, Adelaide Children's HospitalInventors: Raymond John Harris, Charles Phillip Morris
-
Patent number: 5798239Abstract: The present invention provides a highly glycosylated iduronate-2-sulfatase enzyme comprising an iduronate-2-sulfatase polypeptide with at least 5 kilodalton (kDa) more sugar than iduronate-2-sulfatase purified from a natural source, e.g. human liver. The present invention also provides an enzymatically active polypeptide fragment or variant of such a highly glycosylated iduronate-2-sulfatase. The present invention further provides an isolated nucleic acid encoding iduronate-2-sulfatase, as well as an expression vector, a host cell and a method for producing the present highly glycosylated iduronate-2-sulfatase enzyme.Type: GrantFiled: June 7, 1995Date of Patent: August 25, 1998Assignee: Women's and Children's HospitalInventors: Peter J. Wilson, Charles Phillip Morris, Donald Stewart Anson, Teresa Occhiodoro, Julie Bielicki, Peter Roy Clements, John Joseph Hopwood
-
Patent number: 5728381Abstract: The present invention provides a highly glycosylated iduronate-2-sulfatase enzyme comprising an iduronate-2-sulfatase polypeptide with at least 5 kilodalton (kDa) more sugar than iduronate-2-sulfatase purified from a natural source, e.g. human liver. The present invention also provides an enzymatically active polypeptide fragment or variant of such a highly glycosylated iduronate-2-sulfatase. The present invention further provides an isolated nucleic acid encoding iduronate-2-sulfatase, as well as an expression vector, a host cell and a method for producing the present highly glycosylated iduronate-2-sulfatase enzyme.Type: GrantFiled: June 7, 1995Date of Patent: March 17, 1998Inventors: Peter J. Wilson, Charles Phillip Morris, Donald Stewart Anson, Teresa Occhiodoro, Julie Bielicki, Peter Roy Clements, John Joseph Hopwood